(Q33402306)

26 July 2017

title

Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma (English)

1 reference

26 July 2017

1 reference

1 reference

Dong Ta Zhong

1

1 reference

26 July 2017

Chun Mei Shi

2

1 reference

26 July 2017

Qiang Chen

3

1 reference

26 July 2017

Jing Ze Huang

4

1 reference

26 July 2017

Jian Gang Liang

5

1 reference

26 July 2017

language of work or name

1 reference

13 July 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

91

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

1757-1763

1 reference

AIDS-associated non-Hodgkin's lymphoma in San Francisco

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1518-Y

10.1007/S00277-012-1518-Y

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference